AT-43 * MULTI-CENTRE, RANDOMIZED, DOUBLE-BLIND PHASE II STUDY COMPARING CEDIRANIB (AZD2171) PLUS GEFITINIB (IRESSA, ZD1839) WITH CEDIRANIB PLUS PLACEBO IN SUBJECTS WITH RECURRENT/PROGRESSIVE GLIOBLASTOMA

P. Mulholland, D. Krell, I. Khan, C. Mcbain, C. Patel, K. Wanek, K. Hopkins, S. Jeffries, R. Jager, P. Smith, Q. Liu, R. Stupp, I. Tomlinson

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'AT-43 * MULTI-CENTRE, RANDOMIZED, DOUBLE-BLIND PHASE II STUDY COMPARING CEDIRANIB (AZD2171) PLUS GEFITINIB (IRESSA, ZD1839) WITH CEDIRANIB PLUS PLACEBO IN SUBJECTS WITH RECURRENT/PROGRESSIVE GLIOBLASTOMA'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

Agricultural and Biological Sciences